Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment

• Published in: Bioactive materials 2021-11, Vol.6 (11), p.3865-3878
• Main Authors: Zhang, Tao, Liu, Hui, Li, Ling, Guo, Zhaoyang, Song, Jia, Yang, Xiaoying, Wan, Guoyun, Li, Rongshan, Wang, Yinsong
• Format: Article
• Language: English
• Subjects: Chemotherapy; Dendritic large pore mesoporous silica nanoparticles; Leukocyte/platelet hybrid membrane; Phototherapy; Triple-negative breast cancer
• ISSN: 2452-199X; 2452-199X
• DOI: 10.1016/j.bioactmat.2021.04.004

Triple-negative breast cancer (TNBC) is an aggressive subset of breast cancer and currently lacks effective therapeutic targets. As two main phototherapeutic methods, photothermal therapy (PTT) and photodynamic therapy (PDT) show many advantages in TNBC treatment, and their combination with chemotherapy can achieve synergistic therapeutic effects. In the present study, a biomimetic nanoplatform was developed based on leukocyte/platelet hybrid membrane (LPHM) and dendritic large pore mesoporous silicon nanoparticles (DLMSNs). A near infrared (NIR) fluorescent dye IR780 and a chemotherapeutic drug doxorubicin (DOX) were co-loaded into the large pores of DLMSNs to prepare DLMSN@DOX/IR780 (DDI) nanoparticles (NPs), followed by camouflage with LPHM to obtain LPHM@DDI NPs. Through the mediation of LPHM, LPHM@DDI NPs showed an excellent TNBC-targeting ability and very high PTT/PDT performances in vitro and in vivo. Upon NIR laser irradiation, LPHM@DDI NPs exhibited synergistic cytotoxicity and apoptosis-inducing activity in TNBC cells, and effectively suppressed tumor growth and recurrence in TNBC mice through tumor ablation and anti-angiogenesis. These synergistic effects were sourced from the combination of PTT/PDT and chemotherapy. Altogether, this study offers a promising biomimetic nanoplatform for efficient co-loading and targeted delivery of photo/chemotherapeutic agents for TNBC combination treatment. [Display omitted] •A biomimetic nanoplatform was developed from DLMSNs camouflaged with leukocyte/platelet hybrid membrane (LPHM@DLMSNs).•IR780 and doxorubicin were co-loaded into LPHM@DLMSNs to prepare LPHM@DDI nanoparticles (NPs).•LPHM@DDI NPs showed an excellent targeting ability for triple negative breast cancer (TNBC).•LPHM@DDI NPs exerted synergistic effects of PTT/PDT and chemotherapy against TNBC.